Literature DB >> 15493112

[Physiology and biochemistry of uric acid].

M A Hediger1.   

Abstract

In humans, uric acid is the final breakdown product of unwanted purine nucleotides. Uric acid is the last stage in purine degradation, because humans lack the enzyme uricase which converts uric acid into allantoin. Uric acid has profound beneficial effects since it scavenges potential harmful radicals in our body. However, in conjunction with genetic or environmental factors, uric acid can cause significant health problems, leading to kidney stones when it builds up in the kidneys and to gout when crystals accumulate in the joints. The levels of uric acid in the blood must be tightly controlled to minimize these detrimental effects. Normally, the body eliminates enough uric acid in the kidney, and in part also through the intestines, to keep its concentration at a healthy level in the blood (approximately 300 microM). In patients with gout or kidney stone disease, however, the body either produces excessive amounts of uric acid or its ability to eliminate uric acid is disturbed in some way. In the kidney, uric acid is reabsorbed via the uric acid transporter URAT1. This transporter is the major mechanism for regulating blood uric acid levels and therefore may prove an interesting target for future drug development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15493112     DOI: 10.1024/0040-5930.61.9.541

Source DB:  PubMed          Journal:  Ther Umsch        ISSN: 0040-5930


  3 in total

1.  EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.

Authors:  Na Liu; Li Wang; Tao Yang; Chongxiang Xiong; Liuqing Xu; Yingfeng Shi; Wenfang Bao; Y Eugene Chin; Shi-Bin Cheng; Haidong Yan; Andong Qiu; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

2.  Low serum bilirubin, albumin, and uric acid levels in patients with Crohn's disease.

Authors:  Qisheng Su; Xiaohong Li; Wuning Mo; Zheng Yang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

3.  SLC2A9 is a high-capacity urate transporter in humans.

Authors:  Mark J Caulfield; Patricia B Munroe; Deb O'Neill; Kate Witkowska; Fadi J Charchar; Manuel Doblado; Sarah Evans; Susana Eyheramendy; Abiodun Onipinla; Philip Howard; Sue Shaw-Hawkins; Richard J Dobson; Chris Wallace; Stephen J Newhouse; Morris Brown; John M Connell; Anna Dominiczak; Martin Farrall; G Mark Lathrop; Nilesh J Samani; Meena Kumari; Michael Marmot; Eric Brunner; John Chambers; Paul Elliott; Jaspal Kooner; Maris Laan; Elin Org; Gudrun Veldre; Margus Viigimaa; Francesco P Cappuccio; Chen Ji; Roberto Iacone; Pasquale Strazzullo; Kelle H Moley; Chris Cheeseman
Journal:  PLoS Med       Date:  2008-10-07       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.